These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36835933)

  • 1. The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.
    Zhang Z; Xiong Q; Xu Y; Cai X; Zhang L; Zhu Q
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
    Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
    Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma.
    Kaiser J; Hinz U; Mayer P; Hank T; Niesen W; Hackert T; Gaida MM; Büchler MW; Strobel O
    Eur J Surg Oncol; 2021 Jul; 47(7):1734-1741. PubMed ID: 33622577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.
    Silvestris N; Brunetti O; Pinto R; Petriella D; Argentiero A; Fucci L; Tommasi S; Danza K; De Summa S
    Expert Opin Ther Targets; 2018 May; 22(5):453-461. PubMed ID: 29561217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
    Hrudka J; Lawrie K; Waldauf P; Ciprová V; Moravcová J; Matěj R
    Virchows Arch; 2020 Nov; 477(5):687-696. PubMed ID: 32424767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
    Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
    Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
    Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
    Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma.
    Pyo JS; Son BK; Lee HY; Oh IH; Chung KH
    Curr Oncol; 2021 Nov; 28(6):4367-4376. PubMed ID: 34898543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcome and Prognostic Factors of Pancreatic Adenosquamous Carcinoma Compared to Ductal Adenocarcinoma-Results from the German Cancer Registry Group.
    Braun R; Klinkhammer-Schalke M; Zeissig SR; Kleihus van Tol K; Bolm L; Honselmann KC; Petrova E; Lapshyn H; Deichmann S; Abdalla TSA; Heckelmann B; Bronsert P; Zemskov S; Hummel R; Keck T; Wellner UF
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathological features related to onco-immunity and their clinical significance of pancreatic ductal adenocarcinoma].
    Wang CM; Xu CY; Jiang S; Zhou Q; Jiang ZJ; Cheng GP; Wu MJ; Feng TT; Yin WJ
    Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):419-424. PubMed ID: 35511637
    [No Abstract]   [Full Text] [Related]  

  • 14. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
    Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
    Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions.
    Lee SM; Sung CO
    Pancreatology; 2021 Aug; 21(5):920-927. PubMed ID: 33773917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
    Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
    Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
    Shi T; Gao G
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.
    Cai W; Bao W; Chen S; Yang Y; Li Y
    Cancer Cell Int; 2021 Dec; 21(1):698. PubMed ID: 34930261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
    Ko YS; Pyo JS
    Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.